Cortexyme (CRTX) Competitors $1.52 -0.13 (-7.88%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, IKT, PLX, ACHL, IZTC, ZIVO, BLUE, and CYTHShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Achilles Therapeutics (ACHL), Invizyne Technologies (IZTC), ZIVO Bioscience (ZIVO), bluebird bio (BLUE), and Cyclo Therapeutics (CYTH). Cortexyme vs. Its Competitors Omnicell HealthStream Veradigm Inhibikase Therapeutics Protalix BioTherapeutics Achilles Therapeutics Invizyne Technologies ZIVO Bioscience bluebird bio Cyclo Therapeutics Omnicell (NASDAQ:OMCL) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership. Do institutionals and insiders have more ownership in OMCL or CRTX? 97.7% of Omnicell shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 2.5% of Omnicell shares are owned by company insiders. Comparatively, 27.9% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, OMCL or CRTX? Omnicell has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Does the media favor OMCL or CRTX? In the previous week, Omnicell had 2 more articles in the media than Cortexyme. MarketBeat recorded 2 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 0.63 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the media. Company Overall Sentiment Omnicell Positive Cortexyme Neutral Is OMCL or CRTX more profitable? Omnicell has a net margin of 1.87% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 4.60% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets Omnicell1.87% 4.60% 2.56% Cortexyme N/A -70.96%-63.53% Which has stronger valuation & earnings, OMCL or CRTX? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmnicell$1.11B1.25$12.53M$0.4664.78CortexymeN/AN/A-$89.94M-$2.97-0.51 Do analysts prefer OMCL or CRTX? Omnicell presently has a consensus target price of $44.83, indicating a potential upside of 50.45%. Given Omnicell's stronger consensus rating and higher possible upside, research analysts clearly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryOmnicell beats Cortexyme on 13 of the 15 factors compared between the two stocks. Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.83M$201.90M$5.54B$8.87BDividend YieldN/AN/A5.39%4.10%P/E Ratio-0.51N/A26.1719.90Price / SalesN/A240.67413.55113.66Price / CashN/A22.4436.1356.90Price / Book0.385.678.025.38Net Income-$89.94M-$96.61M$3.15B$248.50M7 Day Performance4.83%2.30%1.48%2.06%1 Month Performance43.40%2.56%3.66%4.86%1 Year Performance116.93%19.54%34.68%20.24% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.52-7.9%N/A+109.7%$45.83MN/A-0.5155OMCLOmnicell2.3548 of 5 stars$28.37+1.2%$44.83+58.0%+13.9%$1.31B$1.11B61.683,670HSTMHealthStream4.4123 of 5 stars$27.26+2.5%$31.50+15.6%+0.0%$811.97M$291.65M43.271,093Positive NewsMDRXVeradigm3.1195 of 5 stars$4.49-0.2%$13.00+189.5%-50.3%$486.11M$1.53B0.008,000Positive NewsIKTInhibikase Therapeutics1.3537 of 5 stars$1.66flat$6.50+291.6%+52.9%$123.41M$260K-0.626News CoverageGap UpPLXProtalix BioTherapeutics2.8782 of 5 stars$1.35-3.6%$15.00+1,011.1%+33.3%$107.47M$59.76M-10.38200ACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250IZTCInvizyne TechnologiesN/A$9.15-25.9%N/AN/A$57.21MN/A0.0029Gap UpZIVOZIVO Bioscience0.259 of 5 stars$14.22flatN/A+53.5%$54.22M$15.85K-2.9110Gap UpBLUEbluebird bio2.071 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoverageCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809 Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Inhibikase Therapeutics Alternatives Protalix BioTherapeutics Alternatives Achilles Therapeutics Alternatives Invizyne Technologies Alternatives ZIVO Bioscience Alternatives bluebird bio Alternatives Cyclo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
